1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Oxurion NV
  6. News
  7. Summary
    OXUR   BE0003846632

OXURION NV

(OXUR)
  Report
Real-time Euronext Bruxelles  -  03:04 2022-08-16 am EDT
0.3140 EUR   -0.32%
07/29OXURION NV : Share buyback
CO
07/11Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
GL
07/11Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

06/07/2022 | 01:01pm EDT

Leuven, BELGIUM, Boston, MA, USJUNE 7, 2022 Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022.

The KININ2022 presentation is available under Conferences and Events within the Investors section of the Company’s website.

Overview: THR-149, a bicyclic peptide identified by a combination of phage-based selections and directed medicinal chemistry, is a potent and specific inhibitor of plasma kallikrein. In preclinical studies, THR-149 effectively blocked the release of bradykinin in the vitreous and reduced the level of edema and retinal vascular leakage in rodent models.

Results: IVT-PK and IV-PK data were analyzed based on a mono-compartmental pharmacokinetic model, leading to ocular and systemic half-lives of 36 h and 1.1 h, respectively. The model indicates IVT administration of THR-149 reduces the four DME disease hallmarks: retinal vascular leakage, retinal edema, retinal inflammation and reactive gliosis.

THR-149 is being developed as a potential new standard of care for the up to 50% of diabetic macular edema (DME) patients showing suboptimal response to anti-VEGF therapy. Oxurion is currently evaluating THR-149 for the treatment of DME in Part B, the second part of its two-part Phase 2 KALAHARI trial.

About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.


For more information, please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com

 

Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Beth Kurth
bkurth@conwaycommsir.com

 

 

Westwicke, an ICR Company
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com

Attachment


All news about OXURION NV
07/29OXURION NV : Share buyback
CO
07/11Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
GL
07/11Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
AQ
06/30OXURION NV : Monthly statement on outstanding equity shares and voting rights
CO
06/13Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
AQ
06/13Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
GL
06/13Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
AQ
06/07Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
AQ
06/07Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
GL
06/07Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
AQ
More news
Financials
Sales 2022 0,66 M 0,67 M 0,67 M
Net income 2022 -23,8 M -24,2 M -24,2 M
Net Debt 2022 - - -
P/E ratio 2022 -0,67x
Yield 2022 -
Capitalization 16,1 M 16,4 M 16,4 M
Capi. / Sales 2022 24,5x
Capi. / Sales 2023 24,5x
Nbr of Employees 42
Free-Float 84,6%
Chart OXURION NV
Duration : Period :
Oxurion NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,32 €
Average target price 1,25 €
Spread / Average Target 297%
EPS Revisions
Managers and Directors
Thomas Graney Chief Executive Officer
Patrik de Haes Non-Executive Chairman
Grace Chang Chief Medical Officer
Alan Stitt Chief Scientific Officer
Claude Sander Secretary, Chief Legal & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
OXURION NV-82.65%16
MODERNA, INC.-30.40%66 966
IQVIA HOLDINGS INC.-12.01%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.9.01%31 380
ALNYLAM PHARMACEUTICALS, INC.36.22%28 068